Why Has Wedbush Given Voyager Therapeutics (NASDAQ:VYGR) a $36.0 Price Target
In a note issued to clients today, Wedbush analysts have commenced coverage Voyager Therapeutics (NASDAQ:VYGR) coverage with Outperform rating, and a $36.0 target price.
Approximately 24,255 shares of stock traded hands. Voyager Therapeutics Inc (NASDAQ:VYGR) has risen 6.00% since November 7, 2015 and is uptrending. It has outperformed by 7.08% the S&P500.
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The company has a market cap of $771.28 million. The Firm focuses on developing life-changing treatments for patients suffering from severe diseases of the central nervous system . It currently has negative earnings. The Company’s product engine has generated programs for five CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis; Friedreich’s ataxia; Huntington’s disease, and spinal muscular atrophy.
According to Zacks Investment Research, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.” Get a free copy of the Zacks research report on Voyager Therapeutics Inc (VYGR).